The global oligonucleotide CDMO (Contract Development and Manufacturing Organization) market is on a remarkable growth trajectory. Valued at USD 2.51 billion in 2024, the market is projected to reach USD 6.73 billion by 2029, growing at a CAGR of 21.8%. This rapid expansion underscores the increasing adoption of oligonucleotide-based therapeutics and the growing reliance on CDMOs for their development and production.
Market Growth Drivers
Several key factors are fueling this growth:
-
Rising Outsourcing Trends: Biopharmaceutical companies are increasingly outsourcing the development and manufacturing of oligonucleotides to specialized CDMOs to reduce costs, streamline operations, and accelerate time-to-market.
-
Precision and Personalized Medicine: The growing focus on individualized therapies, particularly in genetic and rare diseases, is propelling demand for oligonucleotide therapeutics such as siRNAs, antisense oligonucleotides (ASOs), and aptamers.
-
Advancements in Therapeutic Development: The surge in R&D investments and commercial launches of oligo-based drugs are further amplifying the need for scalable, compliant, and high-quality CDMO services.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=227700087
Market Landscape: Consolidation and Competition
The oligonucleotide CDMO market is highly consolidated, with major players leveraging innovation, partnerships, and strategic expansions to strengthen their foothold. Prominent companies shaping this landscape include:
Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Agilent Technologies, Inc. (US), Kaneka Eurogentec S.A. (Belgium), Ajinomoto Co., Inc. (Japan), Aurigene Pharmaceutical Services Ltd. (India), Bachem (Switzerland), Syngene International Limited (India), PolyPeptide Group (Switzerland), WuXi AppTec (China), EUROAPI (France), Eurofins Scientific (Luxembourg), GenScript (US), and Danaher Corporation (US).
These companies are pursuing strategies such as product innovation, partnerships, acquisitions, and facility expansions to enhance production capabilities and meet the growing global demand.
Spotlight on Key Market Players
1. Bachem (Switzerland): Specialization in Oligonucleotides and Peptides
Bachem stands out as a specialized CDMO focused on commercial manufacturing of oligonucleotide APIs and peptide-based molecules. The company’s emphasis on advanced technology, regulatory compliance, and large-scale manufacturing capabilities make it a preferred partner for pharma and biotech companies.
A notable example of Bachem’s strategic collaboration is its April 2022 partnership with Eli Lilly, aimed at developing and manufacturing oligonucleotide-based drug substances. This alliance reinforces Bachem’s role as a global leader in oligonucleotide contract manufacturing.
2. Agilent Technologies, Inc. (US): Integrated Oligo CDMO Capabilities
Agilent Technologies delivers a comprehensive suite of oligonucleotide CDMO services, including:
-
Custom oligonucleotide synthesis
-
Process development and optimization
-
Analytical method development and validation
-
Large-scale GMP manufacturing for clinical and commercial use
Agilent’s strong brand recognition, robust manufacturing infrastructure, and global presence position it as a key enabler in advancing next-generation oligonucleotide therapeutics.
3. Thermo Fisher Scientific Inc. (US): End-to-End Manufacturing Excellence
Thermo Fisher Scientific is a market leader in scalable oligonucleotide synthesis and end-to-end manufacturing solutions. Its cutting-edge capabilities include:
-
Solid-phase synthesis for therapeutic oligonucleotides (e.g., ASOs, siRNAs)
-
Proprietary purification technologies ensuring product purity and consistency
-
Automated high-throughput systems for efficient production
The company’s OligoPerfect Primer Designer platform facilitates customized oligonucleotide design, accelerating drug development timelines. Additionally, Thermo Fisher’s expertise in analytical development—using advanced techniques like HPLC, LC-MS, and CE—ensures strict quality control and precise molecular characterization.
With its strong global network and integrated service portfolio, Thermo Fisher continues to lead the oligonucleotide CDMO market, empowering pharmaceutical innovation worldwide.
The Road Ahead
As the therapeutic potential of oligonucleotides continues to expand, the demand for specialized CDMOs will only intensify. With advancements in nucleic acid chemistry, delivery systems, and large-scale GMP manufacturing, CDMOs are poised to play a pivotal role in bridging innovation and commercialization for next-generation therapies.
The oligonucleotide CDMO market is not just growing—it’s transforming the future of precision medicine, enabling the development of life-changing treatments for genetic and rare diseases.